Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 24, 2010 Travers & Jayson	Will Valeant Pharmaceuticals Burn You? How well has Valeant Pharmaceuticals International tapped the capital markets? Here's a visual summary of the past few years
The Motley Fool August 17, 2010 Travers & Jayson	How Long Can Amylin Pharmaceuticals Last? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big.
The Motley Fool August 17, 2010 Travers & Jayson	Is Alexion Pharmaceuticals Burning Out? The first step toward finding a promising biotech company is not to figure out whether the science is any good, but to make sure that the company is financially healthy.
The Motley Fool August 18, 2010 Travers & Jayson	Interested in Elan? Start Here! You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big.
The Motley Fool August 26, 2010 Travers & Jayson	Will Onyx Pharmaceuticals Burn You? Is Onyx Pharmaceuticals on strong financial footing?
The Motley Fool August 17, 2010 Travers & Jayson	Interested in Cephalon ? Start Here! Every biotech company wants to discover the cure for cancer, Alzheimer's, or Wii knee. Every biotech investor hopes to catch the next Valeant Pharmaceuticals.
The Motley Fool August 17, 2010 Travers & Jayson	How Long Can Biovail Last? Stop obsessing about the science.
The Motley Fool August 18, 2010 Travers & Jayson	Will Endo Pharmaceuticals Holdings Burn You? Endo Pharmaceuticals Holdings is cash flow-positive, and has been for quite some time. That's investment nirvana for biotech shareholders.
The Motley Fool August 18, 2010 Charly Travers & Seth Jayson	Will United Therapeutics Burn You? United Therapeutics is cash flow-positive and has mostly been over the past few years. That's investment nirvana for biotech shareholders. This is a rare beast worthy of additional research.
The Motley Fool August 18, 2010 Travers & Jayson	The Most Important Thing About Human Genome Sciences Is Human Genome Sciences on strong financial footing? Take a look.
The Motley Fool August 18, 2010 Travers & Jayson	Will Dendreon Burn You? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. Don't start with the science; ignore the sexy story, and look at the cold, hard cash. How does Dendreon stack up?
The Motley Fool August 26, 2010 Travers & Jayson	Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing?
The Motley Fool February 28, 2011 Brian Orelli	Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out?
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
The Motley Fool April 29, 2005 Charly Travers	Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc.
BusinessWeek May 28, 2009 Catherine Arnst	Make-or-Break Time for Cancer Drugs Strong presentations at the key oncology conference in late May will be crucial for struggling biotechs.
The Motley Fool May 5, 2009 Brian Orelli	The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry.
The Motley Fool April 4, 2009 Brian Orelli	The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
The Motley Fool May 18, 2010 Brian Orelli	What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout.
The Motley Fool December 21, 2004 Charly Travers	Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc.
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
The Motley Fool September 10, 2008 Brian Orelli	Are Drug Companies Being Shortsighted With R&D? Cutting research and development spending could be like playing with fire for pharmaceutical companies.
The Motley Fool January 12, 2005 Charly Travers	Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise.
The Motley Fool November 16, 2004 Charly Travers	Finding Biotech's 50-Baggers Finding these superb biotechs isn't a search for a once-in-a-lifetime opportunity. These great investments pop up a lot more frequently than you may think.
The Motley Fool December 16, 2003 David Nierengarten	Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks.
The Motley Fool March 26, 2004 Charly Travers	Human Genome Getting on Track What a novel concept for a drug company to focus on commercializing drugs.
The Motley Fool October 31, 2006 Brian Lawler	A Look Inside the Biotech Haunted House Even after being warned of the risks, if you're still brave enough to come inside the biotech haunted house, realize that there are surprises. For example, the FDA will spook investors with calls for more clinical trials on drugs that appear to be a lock for approval.
BusinessWeek November 29, 2004 Catherine Arnst	Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs.
The Motley Fool October 27, 2004 Charly Travers	Cubist's Growing Pains The pharmaceutical is going to have to work through some growing pains and make strides toward profitability before the performance of the stock will match the performance of its drug.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
Knowledge@Wharton	The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope...
The Motley Fool October 1, 2008 Brian Orelli	3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear.
The Motley Fool March 22, 2005 Charly Travers	Do Good Drugs Guarantee Investment Success? By the time you know a drug is good, are you late to the party? Instead of trying to catch a train that has already zipped by, try investing in drug programs well in advance of phase 3 trials.
The Motley Fool December 14, 2004 Charly Travers	Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor.
The Motley Fool August 17, 2004 Charly Travers	Surviving Biotech's Downturns Advice on withstanding the volatility of the biotech sector.
The Motley Fool October 9, 2006 Brian Lawler	The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field.
The Motley Fool November 11, 2009 Brian Orelli	Now That's What I Call a Drug Deal Investors are regenerating their interest in Regeneron Pharmaceuticals after it extended its drug-discovery pact with sanofi-aventis.
The Motley Fool January 27, 2011 Rich Smith	What's Behind the Run-Up at Rexahn? The pharmaceutical's hot streak could soon burn up all its cash.
The Motley Fool October 31, 2005 Charly Travers	A Myriad of Shares Management's predilection for excessive share dilution at Myriad Genetics is troubling for investors.
The Motley Fool March 17, 2008 Brian Orelli	Drugmakers That Make Rivals Green with Envy A look at some drugmakers with cash to spend: Pfizer...Wyeth... Novartis... Amylin Pharmaceuticals... Elan...Vertex Pharmaceuticals... Exelixis...
The Motley Fool March 26, 2007 Rich Duprey	Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note.
Inc. May 1, 2002 Kenneth Klee	The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies...
Pharmaceutical Executive October 1, 2005 Brad Miles	Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies.
The Motley Fool March 4, 2004 Brian Gorman	Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates.
The Motley Fool August 2, 2004 Charly Travers	What's a Drug Worth? The value of small biotech companies is in their investigational drug programs.
The Motley Fool July 14, 2005 Charly Travers	Dueling Fools: Protein Design Labs Bull Rebuttal This biotech's tomorrow is coming today. The company is a clear buy at its current market cap near $2 billion.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
The Motley Fool January 25, 2005 Charly Travers	Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs.
The Motley Fool September 12, 2007 Brian Orelli	Fitting Fission at Abraxis BioScience Abraxis BioScience will split itself into a biotech firm and a generic drug business. Both new companies stand to benefit, but will investors?